“The existing condition has uncovered some structural weaknesses while in the EU’s medicines provide chain in addition to a significant dependence on non-EU nations for active pharmaceutical ingredients,” Kyriakides claimed. She suggested that provide chain issues be resolved within an EU pharmaceut